Navigation Links
Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets
Date:5/17/2012

DALLAS, May 17, 2012 /PRNewswire/ --

The "Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study" analyzes and studies the U.S. market for intravenous anesthesia drugs with special focus on ketamine, distribution structure of anesthesia drugs in U.S., potential buyers, export & import system for controlled substances in U.S. and U.S. market entry strategy.

Browse market data tables and in-depth TOC of "Anesthesia Drugs Market (2011 - 2015) - U.S.Market Entry Study".
http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html 

Early buyers will receive 10% customization on reports.

This report studies the U.S. Ketamine market over the period of 2007-2015. Ketamine market is expected to grow at a moderate rate from 2011 to 2016. Anesthesia is a condition in which sensation is totally or partially blocked. This enables the patients to undergo medical procedures and surgery. Based on the applications (type of surgery or medical procedure) anesthetic drugs are broadly categorized into two types; i.e. local anesthetic drugs and general anesthetic drugs. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation.

General anesthesia includes blockage of pain, awareness, and memory. Advantages offered by general anesthesia includes - rapid onset of anesthesia, full control of the body processes (airway, respiratory and circulatory system), used in surgeries with unpredictable duration of surgery, no memory of the surgery, allows complete motionlessness over prolonged duration of the surgery and it permits simultaneous operation on different body parts.

General anesthesia drugs involve inhalation and intravenous anesthesia drugs. Report is specially focused on general intravenous anesthesia drugs category. Drugs such as propofol, midazolam & diazepam, fospropofol disodium, sodium pentothal, ketamine, methohexital sodium, pentobarbital, etomidate, and fentanyl are studied.

The U.S. general anesthesia drugs market size was approximately $2 billion in 2011 and is expected to grow at a moderate rate, with a CAGR of approximately 4% from 2011 to 2015. In addition, intravenous anesthetic drugs accounted for the largest share -65% - of the U.S. general anesthetics drugs market in 2011.

Ketamine is an anesthetic drug mainly used for initiation and maintenance of general anesthesia in humans. It belongs to NMDA receptor antagonist class, which includes molecules that prevent the action of the N-methyl D-aspartate (NMDA) receptor. Factors such as increase in aging population, rising cardiovascular, and respiratory system related diseases and rising number of emergency surgeries will help in maintaining stable growth in the ketamine market revenue in the next five years along with the overall growth of the U.S. general intravenous anesthesia market.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://twitter.com/marketsmarkets


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems
2. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
3. American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia
4. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
5. Researchers reveal why some pain drugs become less effective over time
6. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
7. New drugs show promise for preventing absence seizures in children: UBC research
8. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
9. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
10. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
11. Malaria discovery gives hope for new drugs and vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... and Technology (AGBT) Meeting. --> ... genomic research by providing cost effective NGS library preparation ... a high-throughput, fully integrated, next generation sequencing (NGS) library ...
(Date:2/11/2016)... Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results ... --> --> For the fourth quarter ... or $0.34 loss per share, compared to a net loss of ... in 2014. For the year ended December 31, 2015, the Company ... share, as compared to a net loss of $60.5 million, or ...
(Date:2/11/2016)... BioPharma Selling Solutions (Spectra) is a new Contract ... experience, expertise, operational delivery and customer focus to ... in concert with industry leading commercial experts, the ... needs of its clients by providing value-based creative ... non-personal promotion. --> ...
(Date:2/11/2016)... DELRAY BEACH, Florida , February 11, 2016 ... --> PositiveID Corporation ("PositiveID" or "Company") (OTCQB: ... and diagnostics, announced today that its Thermomedics subsidiary, ... significant progress on its growth plan in January ... healthcare products distributors, increasing sequential monthly sales growth, ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):